Why Psychedelics Might Be the Breakthrough that PTSD Patients Need | Kevin Ryan (The Godfather of NYC Tech)The legendary founder behind MongoDB, Business Insider, and Gilt on how psychedelics are driving breakthrough results in treating depression—and how AI will uncover materials humans never imagined.
Thank you to the partners who make this possibleEnterpret: Transform feedback chaos into actionable customer intelligence. Auth0: Secure access for everyone. But not just anyone. Persona: Trusted identity verification for any use case. Often called the godfather of NYC tech, Kevin Ryan is one of America’s most influential entrepreneurs and investors. He co-founded MongoDB, Business Insider, Gilt Groupe, Zola, and Transcend Therapeutics, and continues to build and back new companies each year through AlleyCorp. Earlier in his career, he led DoubleClick from a 20-person startup to a global leader, taking it public before its acquisition by Google. In this episode, Kevin shares his insights on two surprising pockets of the future that he’s betting on: psychedelics for mental health and AI-powered materials science. He unpacks how psychedelics are showing remarkable success in treating depression and PTSD, and why AI may discover revolutionary new materials, from helicopter blades to smartphone glass, that humans never imagined possible. We explore:
Explore the episodeTimestamps(00:00) Intro (04:30) How Kevin collaborated with Scott Adams (07:11) The origins of AlleyCorp (08:33) The challenge of incubation (10:00) Why intellectual flexibility matters (10:54) What made MongoDB a breakout success (13:49) How shifting market dynamics hurt Gilt’s business (16:22) What Kevin would do differently if he built Gilt again (17:45) Juggling AlleyCorp’s long-term vision with day-to-day demands (20:26) How to make boards more productive (22:25) Why Kevin believes investors should also found companies (24:18) Future spaces Kevin is excited to invest in (25:52) Kevin’s interest in psychedelics and founding Transcend (28:20) Psychedelics for mental health (32:03) How psychedelic therapy is being conducted (34:11) Transcend’s work and the path to approval for methylone (37:47) The challenges of psychedelic research (40:28) How the Trump administration aims to accelerate psychedelic research (41:50) The size and growth of the psychedelic market (44:28) Materials science: What it is, its design tradeoffs, and how AI speeds discovery (49:02) Radical AI’s work creating new compounds (50:34) The industries Radical AI is targeting (52:50) The state of European tech and why it still lags behind (58:26) Final meditations Follow Kevin RyanLinkedIn: https://www.linkedin.com/in/kevinryan3/ Resources and episode mentionsBooks
People
Other resources
Subscribe to the showI’d love it if you’d subscribe and share the show. Your support makes all the difference as we try to bring more curious minds into the conversation. Production and marketing by penname.co. For inquiries about sponsoring the podcast, email [email protected]. You're currently a free subscriber to The Generalist. For the full experience, upgrade your subscription. |